Acurx Pharmaceuticals (3ZO0) Financial Statements
Acurx Pharmaceuticals Financial Overview
Acurx Pharmaceuticals's market cap is currently $5.18M. The company's EPS TTM is $-3.55; its P/E ratio is -0.29; Acurx Pharmaceuticals is estimated to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -8.09M | $ -14.10M | $ -14.58M | $ -12.09M | $ -12.81M |
| EBITDA | $ -7.97M | $ 20.12K | $ -14.58M | $ -12.09M | $ -12.75M |
| Net Income | $ -7.97M | $ -14.10M | $ -14.58M | $ -12.09M | $ -12.75M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 7.56M | $ 3.71M | $ 7.47M | $ 9.11M | $ 12.96M |
| Total Assets | $ 7.69M | $ 3.86M | $ 7.71M | $ 9.38M | $ 13.25M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -7.56M | $ -3.71M | $ -7.47M | $ -9.11M | $ -12.96M |
| Total Liabilities | $ 2.42M | $ 3.24M | $ 3.04M | $ 2.06M | $ 843.91K |
| Stockholders' Equity | $ 5.27M | $ 615.12K | $ 4.67M | $ 7.32M | $ 12.41M |
| Cash Flow | |||||
| Free Cash Flow | $ -6.79M | $ -10.38M | $ -9.80M | $ -7.54M | $ -5.01M |
| Operating Cash Flow | $ -6.79M | $ -10.38M | $ -9.80M | $ -7.54M | $ -5.01M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 10.64M | $ 6.62M | $ 8.16M | $ 3.70M | $ 14.80M |
Currency in USD
